Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for Regenxbio (RGNX) over the last 5 years, with Q3 2025 value amounting to $732000.0.

  • Regenxbio's Gains from Sales and Divestitures rose 8769.23% to $732000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $732000.0, marking a year-over-year increase of 8769.23%. This contributed to the annual value of $395000.0 for FY2024, which is 11584.7% up from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Gains from Sales and Divestitures is $732000.0, which was up 8769.23% from $598000.0 recorded in Q2 2025.
  • Regenxbio's 5-year Gains from Sales and Divestitures high stood at $732000.0 for Q3 2025, and its period low was $68.0 during Q4 2022.
  • Over the past 4 years, Regenxbio's median Gains from Sales and Divestitures value was $183000.0 (recorded in 2023), while the average stood at $277071.2.
  • As far as peak fluctuations go, Regenxbio's Gains from Sales and Divestitures surged by 26901764.71% in 2023, and later skyrocketed by 6703.91% in 2025.
  • Quarter analysis of 4 years shows Regenxbio's Gains from Sales and Divestitures stood at $68.0 in 2022, then surged by 269017.65% to $183000.0 in 2023, then soared by 115.85% to $395000.0 in 2024, then skyrocketed by 85.32% to $732000.0 in 2025.
  • Its last three reported values are $732000.0 in Q3 2025, $598000.0 for Q2 2025, and $546000.0 during Q1 2025.